Adjuvant interferon therapy for malignant melanoma: the debate |
| |
| Authors: | Zhou Qiang Zhang Xiao-Shi |
| |
| Affiliation: | Qiang Zhou1,2,Xiao-Shi Zhang1,2 1 State Key Laboratory of Oncology in South China,Guangzhou,Guangdong 510060,P. R. China,2 Biotherapy Center,Sun Yat-sen University Cancer Center |
| |
| Abstract: | Based on the results of the Kirkwood high-dose interferon alpha-2b (HDI) adjuvant therapy trial of the Eastern Cooperative Oncology Group 1684, the US Food and Drug Administration (FDA) approved HDI as the postoperative adjuvant therapy for high-risk melanoma. Unfortunately, controversies continue regarding the use of interferon (IFN) as adjuvant therapy for melanoma owing to the inconsistent results of subsequent trials. Numerous trials of adjuvant interferon therapy demonstrated a benefit in terms of rela... |
| |
| Keywords: | Interferon melanoma adjuvant therapy clinical trial |
| 本文献已被 CNKI 万方数据 PubMed 等数据库收录！ |
|
